Estimating the Health and Economic Burden of Pneumococcal Diseases Attributable to PCV21 Versus PCV20 or PPSV23 Serotypes Among Adults in Norway

20250 citationsJournal Articlegold Open Access

Authors

Zinan Yi · Merck & Co., Inc., Rahway, NJ, USA (United States)

Kwame Owusu‐Edusei · Merck & Co., Inc., Rahway, NJ, USA (United States)

Abstract

Compared with PCV20 and PPSV23, PCV21 serotypes are associated with a higher health and economic burden in Norway. The inclusion of PCV21 into national vaccine recommendations in Norway can further alleviate the burden associated with PD in adults.

Topics & Keywords

Pneumonia and Respiratory Infections Respiratory viral infections research Influenza Virus Research Studies

Publication Details

Published in: Infectious Diseases and Therapy

Volume 15, Issue 2, pp. 477-490

DOI: 10.1007/s40121-025-01275-3

Field-Weighted Citation Impact: 0.00

Command Palette

Estimating the Health and Economic Burden of Pneumococcal Diseases Attributable to PCV21 Versus PCV20 or PPSV23 Serotypes Among Adults in Norway

Authors

Abstract

Topics & Keywords

Publication Details